Prelude Stock
Prelude delivers actionable tools to manage early stage breast cancer with the DCIS test that enables personalized treatment.
Sign up today and learn more about Prelude Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Prelude Stock
PreludeDx was founded with the goal of providing better decision-making tools to breast cancer patients and physicians. Founded in 2009 with technology licensed from the University of California San Francisco, PreludeDx has focused on developing breast cancer tools that will impact a patient’s treatment decision. Their mission is to provide tools that improve patient outcomes in breast cancer and reduce the overall cost burden to the healthcare system.
Funding History
| February 2016 | $2.1M |
|---|---|
| March 2022 | $20.0M |
Management
Board of Director
Alejandro Sanchez
Chief Commercial Officer
Edwin Hendrick
CFO
Andy Wade
CEO
Dan Forche
Press
prnewswire - Apr, 14 2024
PreludeDx™ Presents New Data Demonstrating Utility of DCISionRT® to De-escalate Radiation Therapy for Women with DCISprnewswire - Feb, 8 2024
PreludeDx Appoints Chris Emery, VP of Strategic Marketing and Business DevelopmentEquityZen Recognized As:
